222 related articles for article (PubMed ID: 8573583)
1. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.
Davis JP; Cain GA; Pitts WJ; Magolda RL; Copeland RA
Biochemistry; 1996 Jan; 35(4):1270-3. PubMed ID: 8573583
[TBL] [Abstract][Full Text] [Related]
2. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
Knecht W; Löffler M
Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Greene S; Watanabe K; Braatz-Trulson J; Lou L
Biochem Pharmacol; 1995 Sep; 50(6):861-7. PubMed ID: 7575649
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of beta-hydroxy-propenamide derivatives and the inhibition of human dihydroorotate dehydrogenase.
Kim TH; Na HS; Löffler M
Arch Pharm Res; 2003 Mar; 26(3):197-201. PubMed ID: 12723931
[TBL] [Abstract][Full Text] [Related]
5. Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase.
McLean JE; Neidhardt EA; Grossman TH; Hedstrom L
Biochemistry; 2001 Feb; 40(7):2194-200. PubMed ID: 11329288
[TBL] [Abstract][Full Text] [Related]
6. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner.
Hamilton LC; Vojnovic I; Warner TD
Br J Pharmacol; 1999 Aug; 127(7):1589-96. PubMed ID: 10455314
[TBL] [Abstract][Full Text] [Related]
7. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells.
Baumann P; Mandl-Weber S; Völkl A; Adam C; Bumeder I; Oduncu F; Schmidmaier R
Mol Cancer Ther; 2009 Feb; 8(2):366-75. PubMed ID: 19174558
[TBL] [Abstract][Full Text] [Related]
8. The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage.
Kobayashi Y; Ueyama S; Arai Y; Yoshida Y; Kaneda T; Sato T; Shin K; Kumegawa M; Hakeda Y
J Bone Miner Metab; 2004; 22(4):318-28. PubMed ID: 15221489
[TBL] [Abstract][Full Text] [Related]
9. The active metabolite of leflunomide A771726 inhibits corneal neovascularization.
Zhang M; Hao N; Bian F
J Huazhong Univ Sci Technolog Med Sci; 2008 Jun; 28(3):364-8. PubMed ID: 18563344
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
Knecht W; Henseling J; Löffler M
Chem Biol Interact; 2000 Jan; 124(1):61-76. PubMed ID: 10658902
[TBL] [Abstract][Full Text] [Related]
11. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice.
Xu X; Blinder L; Shen J; Gong H; Finnegan A; Williams JW; Chong AS
J Immunol; 1997 Jul; 159(1):167-74. PubMed ID: 9200452
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in Vivo inhibition of immunoglobulin secretion by the immunosuppressive compound HR325 is reversed by exogenous uridine.
Thomson TA; Spinella-Jaegle S; Francesconi E; Meakin C; Millet S; Flao KL; Hidden H; Ruuth E
Scand J Immunol; 2002 Jul; 56(1):35-42. PubMed ID: 12100469
[TBL] [Abstract][Full Text] [Related]
13. Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance.
Kis E; Nagy T; Jani M; Molnár E; Jánossy J; Ujhellyi O; Német K; Herédi-Szabó K; Krajcsi P
Ann Rheum Dis; 2009 Jul; 68(7):1201-7. PubMed ID: 18397960
[TBL] [Abstract][Full Text] [Related]
14. [The active metabolite of leflunomide A771726 inhibits proliferation and collagen synthesis of hepatic stellate cell].
Yao HW; Li J; Chen JQ; Xu SY
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 33(6):515-8, 528. PubMed ID: 15586409
[TBL] [Abstract][Full Text] [Related]
15. Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide.
Schorlemmer HU; Milbert U; Zeitter D; Haun G; Wunschel M; Bartlett RR
Inflamm Res; 1999 Dec; 48 Suppl 2():S115-6. PubMed ID: 10667841
[No Abstract] [Full Text] [Related]
16. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.
Manna SK; Aggarwal BB
J Immunol; 1999 Feb; 162(4):2095-102. PubMed ID: 9973483
[TBL] [Abstract][Full Text] [Related]
17. Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells.
Dietrich S; Krämer OH; Hahn E; Schäfer C; Giese T; Hess M; Tretter T; Rieger M; Hüllein J; Zenz T; Ho AD; Dreger P; Luft T
Clin Cancer Res; 2012 Jan; 18(2):417-31. PubMed ID: 22072733
[TBL] [Abstract][Full Text] [Related]
18. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
Cherwinski HM; Cohn RG; Cheung P; Webster DJ; Xu YZ; Caulfield JP; Young JM; Nakano G; Ransom JT
J Pharmacol Exp Ther; 1995 Nov; 275(2):1043-9. PubMed ID: 7473131
[TBL] [Abstract][Full Text] [Related]
19. Structural and functional comparison of agents interfering with dihydroorotate, succinate and NADH oxidation of rat liver mitochondria.
Jöckel J; Wendt B; Löffler M
Biochem Pharmacol; 1998 Oct; 56(8):1053-60. PubMed ID: 9776318
[TBL] [Abstract][Full Text] [Related]
20. [Inhibition of leflunomide active metabolite A771726 on high glucose-induced podocyte apoptosis].
Yuan YC; Yu WM; Li RS; Qiao X
Zhonghua Yi Xue Za Zhi; 2011 Mar; 91(10):703-6. PubMed ID: 21600180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]